Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \< 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies +/- chemotherapies (CT)), vast majority of patients relapsed and received diverse CT producing modest benefits, and nearly all patients will die. After first line CT including platinum salt, monotherapy (doxorubicin or paclitaxel) is frequently used for relapsed patients, but the response rate (RR) is \<20%, progression-free survival (PFS) \<4 months, and OS \<1 year. In this unmet need situation, a better knowledge of these aggressive neoplasms is essential to propose new therapeutic options.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histopatologicznie rak macicy typu carcinosarcoma (złośliwy mieszany guz Müllera)
- •Progresja lub nawrót choroby zgodnie z kryteriami RECIST 1.1
- •Wcześniejsze leczenie platynowymi chemioterapiami (co najmniej jeden schemat)
- •Stan ogólny pacjenta oceniony na skali ECOG 0 lub 1 (pacjent potrafi wykonywać codzienne czynności)
- •Przewidywana długość życia ponad 2 miesiące
- •Prawidłowe wartości morfologii krwi (płytki ≥100 000/mm3, neutrofile ≥1500/mm3, hemoglobina >9 g/dL)
- •Prawidłowa funkcja wątroby i nerek (bilirubin, kreatynina, enzymy wątrobowe w normie lub lekko podwyższone)
- •Dostępna próbka guza do analizy laboratoryjnej
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (36)
ICO Paul Papin
Angers, France
CHRU Jean Minjoz
Besançon, France
Centre Régional de Lutte contre le cancer - Institut Bergonié
Bordeaux, France
CHU de BREST - Hôpital Cavale Blanche
Brest, France
Centre François Baclesse
Caen, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
CHU de Limoges - Hôpital Dupuytren
Limoges, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Hôpital Privé du Confluent S.A.S.
Nantes, France
Centre Hospitalier Universitaire de Nîmes, Institut de Cancérologie du GARD
Nîmes, France
Groupe Hospitalier des Diaconesses Croix Saint-Simon
Paris, France
Institut Curie
Paris, France
Hopital Milétrie - Centre Hospitalier Universitaire Poitiers
Poitiers, France
Centre Eugène Marquis
Rennes, France
ICO - Centre René Gauducheau
Saint-Herblain, France
CHU Saint-Etienne - Pôle de Cancérologie
Saint-Priest-en-Jarez, France
ICANS
Strasbourg, France
Hôpitaux Universitaires de Strasbourg
Strasbourg, France
IUCT Oncopole - Institut Claudius Régaud
Toulouse, France
ICL - Centre Alexis Vautrin
Vandœuvre-lès-Nancy, France
Institut Gustave Roussy
Villejuif, France
Azienda Ospedaliero-Universitaria di Bologna IRCCS Istituto di Ricerca e di Cura a Carattere Scientifico
Bologna, Italy
Azienda Ospedaliera Per L'Emergenza Cannizzaro
Catania, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Meldola, Italy
Ospedale San Raffaele S.r.l.
Milan, Italy
Humanitas Mirasole S.p.A.
Milan, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Naples, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Azienda Ospedaliera Ordine Mauriziano Di Torino
Torino, Italy
Hospital Universitario Ramon Y Cajal
Madrid, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
Hospital Virgen de la Arrixaca
Murcia, Spain
Hospital Clinico Universitario De Valencia
Valencia, Spain
Trial contact
Isabelle RAY-COQUARD, Professor
Sébastien ARMANET
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.